Free Trial

Novo Nordisk (NOVOB: A1/AA-): Denmark Restricting Ozempic

HEALTHCARE

The Danish health system is now spending 8% of its medicine budget on Wegovy.

  • The push back has begun with the Danish Medicines Agency advising doctors to attempt alternative treatments before using weight loss drugs.
  • New rules come into force in November but Berlingske is reporting a change in guidance is already in place.
  • It will be hard to stop the juggernaut that is Ozempic but remain vigilant about other health authorities following.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.